---
title: "Dogwood Therapeutics announces press release availability"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293214439.md"
description: "Dogwood Therapeutics has enrolled the first 200 patients in its Phase 2b HAL-CINP trial for chemotherapy-induced neuropathic pain. Top-line results from the four-week study are targeted for fall 2026. An independent unblinded statistical review in December indicated separation from placebo regarding pain improvement, with a dropout rate of 4.5%."
datetime: "2026-07-20T12:31:17.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293214439.md)
  - [en](https://longbridge.com/en/news/293214439.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293214439.md)
generator: "portal-rs"
---

# Dogwood Therapeutics announces press release availability

-   Dogwood Therapeutics enrolled the first 200 patients in its Halneuron Phase 2b HAL-CINP trial for chemotherapy-induced neuropathic pain. \* Top-line results from the four-week study remain targeted for fall 2026. \* An independent unblinded statistical review in December flagged separation from placebo on pain improvement; dropout rate reported at 4.5%. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dogwood Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607200830PRIMZONEFULLFEED9764133) on July 20, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [DWTX.US](https://longbridge.com/en/quote/DWTX.US.md)

## Related News & Research

- [Dogwood Therapeutics (NASDAQ:DWTX) Releases Earnings Results, Misses Estimates By $0.21 EPS](https://longbridge.com/en/news/295832761.md)
- [Dogwood Therapeutics posts corporate presentation on non-opioid pain, neuropathy drug pipeline](https://longbridge.com/en/news/294730030.md)
- [Dogwood Therapeutics to host virtual KOL event on Halneuron for chemotherapy-induced neuropathic pain](https://longbridge.com/en/news/296106790.md)
- [Pelthos Therapeutics announces annual shareholder meeting](https://longbridge.com/en/news/296270309.md)
- [Palvella Therapeutics COO Kathleen Goin reports sale of 4,302 common shares worth $654,184.41](https://longbridge.com/en/news/296530942.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**